Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles
European Journal of Immunology · 2026
DOI: 10.1002/eji.70231 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Immunology, 2026. Verfasst von Marco Mannes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical and Experimental Trauma-Immunology, Ulm University Medical Center, Ulm, Germany. Hauptthemen laut MEDLINE: Complement System Proteins, Complement Activation, Precision Medicine, Complement Inactivating Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI Future Leaders Fellowship Award.
Abstract (Originalsprache)
The landscape of complement therapeutics has significantly broadened in recent years; systemically acting stoichiometric inhibitors against complement proteins across almost the entire complement cascade are now available. However, despite their unquestionable clinical success, several limitations remain, including increased infection risks, loss of physiological functions, and clinically observed breakthrough events. In addition, many complement diseases require lifelong treatment, further amplifying the overall healthcare burden and motivating the development of alternative concepts for more precision‐based therapies. Given that many complement‐associated diseases primarily manifest in specific body compartments, directing complement intervention to an organ, tissue, or even a particular cell type represents an important goal. In this article, we briefly delineate the status of approved complement therapeutics and review preclinical progress in emerging concepts. We highlight several key properties that are essential for achieving targeted complement therapies: administration routes, tissue/cell penetration, specificity, and the mode of action. In addition to approaches aimed at dampening complement activation, we outline strategies designed to specifically activate complement locally, for example, in the context of cancer. Together, these insights underscore the growing potential of next‐generation complement therapeutics to achieve more precise and effective clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical and Experimental Trauma-Immunology, Ulm University Medical Center, Ulm, Germany.
- UK Dementia Research Institute at Cardiff University, School of Medicine, Cardiff University, Cardiff, UK.
- Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Marco Mannes, Wioleta M Zelek, Leendert A Trouw
Förderung
- UKRI Future Leaders Fellowship Award
Zitieren
APA
Mannes, M., Zelek, W. M., & Trouw, L. A. (2026). Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles. European Journal of Immunology. https://doi.org/10.1002/eji.70231
Vancouver
Mannes M, Zelek WM, Trouw LA. Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles. European Journal of Immunology. 2026. doi:10.1002/eji.70231
BibTeX
@article{Mannes2026,
author = {Mannes, Marco and Zelek, Wioleta M and Trouw, Leendert A},
title = {Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles},
journal = {European Journal of Immunology},
year = {2026},
doi = {10.1002/eji.70231}
}
EUVIMED